NALFURAFINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H32N2O5.ClH
Molecular Weight	513.025
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC6CC6)[C@H]1O5)C(=O)\C=C\C7=COC=C7

InChI

InChIKey=DJSFYNINGIMKAG-FQJQBBMWSA-N

InChI=1S/C28H32N2O5.ClH/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17;/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3;1H/b7-4+;/t20-,22-,26+,27+,28-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C28H32N2O5
Molecular Weight	476.5641
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	1
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26005355 | https://www.ncbi.nlm.nih.gov/pubmed/19584962 | http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/002683/WC500162688.pdf

Nalfurafine, an opioid κ-selective agonist, has been officially approved for resistant pruritus in HD patients on the basis of a well-evidenced clinical trial in Japan. Nalfurafine hydrochloride is a potent and selective agonist for mouse, rat, guinea pig, and human κ-opioid receptors without significant activity on µ- and δ-opioid receptors. Nalfurafine hydrochloride (2.5 and 5 ug/day) has been proven to be safe and effective for the treatment of HD patients with uremic pruritus resistant to antihistamines.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Kappa opioid receptor 115 Target ID: CHEMBL237 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/002683/WC500162688.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15383632	Agonist 2752		25.0 pM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pruritus in hemodialysis patients 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26005355 https://www.ncbi.nlm.nih.gov/pubmed/19584962	Primary		Approved 8583	REMITCH Approved Use Improvement of pruritus in hemodialysis patients (only for cases resistant to conventional treatments) Launch Date 2009

C_max

Value	Dose	Analyte	Population
12.67 pg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/480220_1190015M1029_1_A13_1F.pdf#page=40 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=376	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.68 pg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/480220_1190015M1029_1_A13_1F.pdf#page=40 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=376	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
209.37 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=361	30 μg single, intravenous dose: 30 μg route of administration: Intravenous experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.85 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=361	30 μg single, oral dose: 30 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
19.1 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.1 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	20 μg single, oral dose: 20 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
90.3 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	40 μg single, oral dose: 40 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.52 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	10 μg 1 times / day multiple, oral dose: 10 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.68 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	10 μg 1 times / day multiple, oral dose: 10 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
28.8 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	20 μg 1 times / day multiple, oral dose: 20 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
33.8 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	20 μg 1 times / day multiple, oral dose: 20 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.15 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	2.5 μg 1 times / day multiple, oral dose: 2.5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
5.7 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	2.5 μg 1 times / day multiple, oral dose: 2.5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.51 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	5 μg 1 times / day multiple, oral dose: 5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
10.25 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	5 μg 1 times / day multiple, oral dose: 5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3.63 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=469	2.5 μg single, oral dose: 2.5 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.76 pg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=469	5 μg single, oral dose: 5 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
114.46 pg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/480220_1190015M1029_1_A13_1F.pdf#page=40 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=376	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
126.03 pg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/480220_1190015M1029_1_A13_1F.pdf#page=40 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=376	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
666.03 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=361	30 μg single, intravenous dose: 30 μg route of administration: Intravenous experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
387.45 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=361	30 μg single, oral dose: 30 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
297 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
604 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	20 μg single, oral dose: 20 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
967 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	40 μg single, oral dose: 40 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
73.9 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	10 μg 1 times / day multiple, oral dose: 10 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
66.1 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	10 μg 1 times / day multiple, oral dose: 10 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
324 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	20 μg 1 times / day multiple, oral dose: 20 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
436 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	20 μg 1 times / day multiple, oral dose: 20 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
66.26 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	2.5 μg 1 times / day multiple, oral dose: 2.5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
210.25 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	2.5 μg 1 times / day multiple, oral dose: 2.5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
120.59 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	5 μg 1 times / day multiple, oral dose: 5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
358.86 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	5 μg 1 times / day multiple, oral dose: 5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
34.58 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=469	2.5 μg single, oral dose: 2.5 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
58.06 pg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=469	5 μg single, oral dose: 5 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
5.99 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/480220_1190015M1029_1_A13_1F.pdf#page=40 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=376	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.9 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/480220_1190015M1029_1_A13_1F.pdf#page=40 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=376	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7.93 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=361	30 μg single, intravenous dose: 30 μg route of administration: Intravenous experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.27 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=361	30 μg single, oral dose: 30 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.75 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	10 μg single, oral dose: 10 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.1 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	20 μg single, oral dose: 20 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.5 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	40 μg single, oral dose: 40 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.78 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	10 μg 1 times / day multiple, oral dose: 10 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.77 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	10 μg 1 times / day multiple, oral dose: 10 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.08 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	20 μg 1 times / day multiple, oral dose: 20 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.6 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	20 μg 1 times / day multiple, oral dose: 20 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.21 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	2.5 μg 1 times / day multiple, oral dose: 2.5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
25.33 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	2.5 μg 1 times / day multiple, oral dose: 2.5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
14.03 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	5 μg 1 times / day multiple, oral dose: 5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
28.34 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	5 μg 1 times / day multiple, oral dose: 5 μg route of administration: Oral experiment type: MULTIPLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
5.37 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=469	2.5 μg single, oral dose: 2.5 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.61 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=469	5 μg single, oral dose: 5 μg route of administration: Oral experiment type: SINGLE co-administered:	NALFURAFINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
23.7% OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_I100_1.pdf#page=105			NALFURAFINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
5 ug 1 times / day multiple, oral Recommended Dose: 5 ug, 1 times / day Route: oral Route: multiple Dose: 5 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19926718/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/19926718/	Disc. AE: Insomnia... AEs leading to discontinuation/dose reduction: Insomnia (1.75%) Sources: https://pubmed.ncbi.nlm.nih.gov/19926718/
5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	Disc. AE: Electrocardiogram abnormal, Myasthenia gravis... AEs leading to discontinuation/dose reduction: Electrocardiogram abnormal Myasthenia gravis Lacrimation increased Muscle spasms Hyperhidrosis Somnolence Paraesthesia Headache Insomnia Nightmare Vomiting Fatigue Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf

AEs

AE	Significance	Dose	Population
Insomnia	1.75% Disc. AE	5 ug 1 times / day multiple, oral Recommended Dose: 5 ug, 1 times / day Route: oral Route: multiple Dose: 5 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19926718/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/19926718/
Electrocardiogram abnormal	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Fatigue	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Headache	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Hyperhidrosis	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Insomnia	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Lacrimation increased	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Muscle spasms	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Myasthenia gravis	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Nightmare	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Paraesthesia	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Somnolence	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf
Vomiting	Disc. AE	5 ug 3 times / week multiple, intravenous Recommended Dose: 5 ug, 3 times / week Route: intravenous Route: multiple Dose: 5 ug, 3 times / week Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf

PubMed

Title	Date	PubMed
Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies.	2012-08-01	22742909
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.	2009-10-12	19686730
Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.	2006-09	16919318
Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.	2005-01	15383632

Patents

Sample Use Guides

In Vivo Use Guide

The usual oral dosage for adults is 2.5 ug of nalfurafine hydrochloride, once a day, after supper or before sleep. The dosage may be adjusted according to symptoms provided that it does not exceed 5 ug once a day.

Route of Administration: Oral

In Vitro Use Guide

Nalfurafine hydrochloride inhibited the electrically-induced contraction of mouse vas deferens with the IC50 of 0.080 nmol/L and 0.12 nmol/L in two independent experiments in vitro.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:58:02 GMT 2025` Edited by `admin` on `Mon Mar 31 17:58:02 GMT 2025`
Record UNII	25CC4N0P8J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NALFURAFINE HYDROCHLORIDE

Official Name

English

NALFURAFINE HYDROCHLORIDE [JAN]

Preferred Name

English

2-PROPENAMIDE, N-((5.ALPHA.,6.BETA.)-17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-3,14-DIHYDROXYMORPHINAN-6-YL)-3-(3-FURANYL)-N-METHYL-, MONOHYDROCHLORIDE, (2E)-

Common Name

English

(-)-17-(CYCLOPROPYLMETHYL-3,14.BETA.-DIHYDROXY-4,5.ALPHA.-EPOXY-6.BETA.-(N-METHYL-TRANS-3-(3-FURYL)ACRYLAMID)MORPHINAN HYDROCHLORIDE

Common Name

English

NALFURAFINE HCL

Common Name

English

NALFURAFINE HYDROCHLORIDE [MART.]

Common Name

English

NALFURAFINE HYDROCHLORIDE [MI]

Common Name

English

NALFURAFINE HYDROCHLORIDE [USAN]

Common Name

English

TRK-820

Code

English

REMITCH

Brand Name

English

Nalfurafine hydrochloride [WHO-DD]

Common Name

English

(E)-N-[17-(Cyclopropylmethyl)-4,5?-epoxy-3,14-dihydroxymorphinan-6?-yl]-3-(furan-3-yl)-N-methylprop-2-enamide monohydrochloride

Systematic Name

English

NOPICOR

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67413